Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase 1/2 Terminated 200 enrolled AbbVie

NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

Timeline

Start: 2016-09-23
Primary completion: 2019-08-27
Completion: 2019-08-27

Publications

Xie H, Kaye FJ, Isse K, Sun Y, Ramoth J, French DM, Flotte TJ, Luo Y, Saunders LR, Mansfield AS. Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. Oncologist. 2020 Sep;25(9):810-817. doi: 10.1634/theoncologist.2019-0877. Epub 2020 May 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rovalpituzumab tesirine	Other / unclassified	0.2 mg/kg	Intravenous
Subject	Rovalpituzumab tesirine	Other / unclassified	0.4 mg/kg	Intravenous
Background	Dexamethasone	Small molecule	8 mg	Oral

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Summary

Timeline

Publications

Drugs

Indications